A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer ; volume:9 ; number:1 ; day:24 ; month:1 ; year:2019 ; pages:1-11 ; date:12.2019
Scientific reports ; 9, Heft 1 (24.1.2019), 1-11, 12.2019
- Klassifikation
-
Naturwissenschaften
- Urheber
-
Park, Jieun
Cho, Yong-Hee
Shin, Wook-Jin
Lee, Sang-Kyu
Lee, JaeHeon
Kim, Taehyung
Cha, Pu-Hyeon
Yang, Jee Sun
Cho, Jaebeom
Min, Do Sik
Han, Gyoonhee
Lee, Ho-Young
Choi, Kang-Yell
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-37059-8
- URN
-
urn:nbn:de:101:1-2019022222594881736268
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Park, Jieun
- Cho, Yong-Hee
- Shin, Wook-Jin
- Lee, Sang-Kyu
- Lee, JaeHeon
- Kim, Taehyung
- Cha, Pu-Hyeon
- Yang, Jee Sun
- Cho, Jaebeom
- Min, Do Sik
- Han, Gyoonhee
- Lee, Ho-Young
- Choi, Kang-Yell
- SpringerLink (Online service)
Ähnliche Objekte (12)
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor
Exosomes: a new perspective in EGFR-mutated lung cancer
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor
Exosomes: a new perspective in EGFR-mutated lung cancer
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor